SAMBA II SARS-CoV-2即时检测性能评估
该研究评估了SAMBA II SARS-CoV-2即时检测的分析灵敏度与临床性能,并与Public Health England的实时PCR法比较。在172份残余鼻/咽拭子中,阳性符合率98.9%(95%CI 93.83-99.97),阴性符合率96.4%(95%CI 89.92-99.26),周转时间86至101分钟,与集中检测等效。
要点
- 分析灵敏度为250 copies/ml,可检测ORF1ab和N两个基因组区域。
- 与实时PCR相比,阳性符合率98.9%,阴性符合率96.4%。
- 周转时间86至101分钟,适合快速分诊和感染控制决策。
核心结论
- SAMBA II SARS-CoV-2检测性能与集中式检测方法等效,且周转时间更短。
研究设计与样本
- 通过计算机模拟引物探针分析和湿实验确定包容性与特异性,并评估性能特征。
- 临床性能在172份残余鼻/咽拭子中评估,与Public Health England靶向RdRp基因的实时PCR法比较。
主要发现
- 分析灵敏度为250 copies/ml,可检测ORF1ab和N两个基因组区域。
- 临床性能评估显示阳性符合率98.9%(95%CI 93.83-99.97),阴性符合率96.4%(95%CI 89.92-99.26)。
- 周转时间为86至101分钟。
关键数值与推荐
- 分析灵敏度250 copies/ml(检测ORF1ab和N两个区域)。
- 阳性符合率98.9%(95%CI 93.83-99.97),阴性符合率96.4%(95%CI 89.92-99.26)。
- 周转时间86至101分钟。
临床怎么用
- 可用于需要快速分诊和感染控制决策的场景,实现快速患者管理和感染控制措施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nucleic acid amplification for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA in respiratory samples is the standard method for diagnosis. The majority of this testing is centralized and therefore has turnaround times of several days. Point-of-care (POC) testing with rapid turnaround times would allow more effective triage in settings where patient management and infection control decisions need to be made rapidly. The inclusivity and specificity of the Simple AMplification-Based Assay (SAMBA) II SARS-CoV-2 test were determined by both in silico analyses of the primers and probes and wet testing. The SAMBA II SARS-CoV-2 test was evaluated for performance characteristics. Clinical performance was evaluated in residual combined throat/nose swabs and compared to that of the Public Health England real-time PCR assay targeting the RdRp gene. The SAMBA II SARS-CoV-2 test has an analytical sensitivity of 250 copies/ml for detecting two regions of the genome (open reading frame 1ab [ORF1ab] and nucleocapsid protein [N]). The clinical performance was evaluated in 172 residual combined nose/throat swabs provided by the Clinical Microbiology and Public Health Laboratory, Addenbrooke's Hospital, Cambridge (CMPHL), which showed an estimated positive percent agreement of 98.9% (95% confidence interval [CI], 93.83 to 99.97) and negative percent agreement of 96.4% (95% CI, 89.92 to 99.26) compared to testing by the CMPHL. The data show that the SAMBA II SARS-CoV-2 test performs equivalently to the centralized testing methods, but with a shorter turnaround time of 86 to 101 min. Point-of-care tests such as SAMBA should enable rapid patient management and effective implementation of infection control measures.
引用
- Assennato SM, Ritchie AV, Nadala C, et al. Performance Evaluation of the SAMBA II SARS-CoV-2 Test for Point-of-Care Detection of SARS-CoV-2. J Clin Microbiol. 2020. PMID: 33051242. doi:10.1128/JCM.01262-20
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。